Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

被引：0
|
作者：
Eric S. Daar [1 ]
Chloe Orkin [2 ]
Paul E. Sax [3 ]
Debbie Hagins [4 ]
Anton Pozniak [5 ]
Kimberly Workowski [6 ]
Cynthia Brinson [7 ]
Juan Manuel Tiraboschi [8 ]
Hui Liu [9 ]
Chris Deaton [10 ]
Cal Cohen [10 ]
Sharline Madera [10 ]
Jason T. Hindman [10 ]
Moti Ramgopal [10 ]
机构：
[1] Lundquist Institute at Harbor-UCLA Medical Center,
[2] Queen Mary University of London,undefined
[3] Brigham and Women’s Hospital,undefined
[4] Coastal CARE Centers,undefined
[5] Chelsea and Westminster Hospital,undefined
[6] London School of Hygiene and Tropical Medicine,undefined
[7] Emory University,undefined
[8] Central Health,undefined
[9] Hospital Universitari de Bellvitge,undefined
[10] Gilead Sciences,undefined
[11] Inc.,undefined
[12] Midway Research Center and Midway Specialty Care Center,undefined
来源：
AIDS Research and Therapy | / 22卷 / 1期
关键词：
Antiretroviral therapy; Bictegravir; Body mass index; Dolutegravir; Glucose; HIV-1; Tenofovir alafenamide;
D O I：
10.1186/s12981-025-00732-w
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy
    Truong, David
    Yi, Shana
    Wiesmann, Christina
    Conway, Brian
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 181 - 181
  • [22] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P. E.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J. L.
    Stellbrink, H-J
    Dejesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D. M.
    Collins, S. E.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 94 - 95
  • [23] Satisfaction and knowledge of patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
    Velez-Diaz-Pallares, Manuel
    Gramage-Caro, Teresa
    Angel Rodriguez-Sagrado, Miguel
    Montero-Llorente, Beatriz
    Bermejo-Vicedo, Teresa
    BIOMEDICA, 2020, 40
  • [24] Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study
    Monforte, Antonella D'arminio
    Tavelli, Alessandro
    Sala, Matteo
    Mondi, Annalisa
    Rusconi, Stefano
    Antinori, Spinello
    Puoti, Massimo
    Celesia, Benedetto Maurizio
    Taramasso, Lucia
    Saracino, Annalisa
    Antinori, Andrea
    Cozzi-Lepri, Alessandro
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (04) : 933 - 945
  • [25] Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
    Calza, Leonardo
    Bon, Isabella
    Pensalfine, Giulia
    Vitale, Salvatore
    Appolloni, Lucia
    Viale, Pierluigi
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 (04) : E9 - E11
  • [26] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J.
    Stellbrink, H-J
    DeJesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2020, 21 : 18 - 18
  • [27] Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
    Knobel, Hernando
    Canas-Ruano, Esperanza
    Guelar, Ana
    Knobel, Pablo
    Villar-Garcia, Judit
    Gonzalez-Mena, Alicia
    Canepa, Ceclia
    Arrieta-Aldea, Itziar
    Marcos, Augustin
    Abalat-Torrres, Agusti
    Gerri-Fernandez, Roberto
    HIV RESEARCH & CLINICAL PRACTICE, 2023, 24 (01)
  • [28] Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
    Hsu, Jen-Yu
    Sun, Hsin-Yun
    Chen, Ling-Ya
    Chang, Sui-Yuan
    Chuang, Yu -Chung
    Huang, Yu -Shan
    Su, Yi-Ching
    Liu, Wen -Chun
    Hung, Chien -Ching
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 36 : 426 - 435
  • [29] Adherence and Forgiveness of Two Modern ART Regimens: Lamivudine/Dolutegravir and Emtricitabine/Tenofovir Alafenamide/Rilpivirine
    Taramasso, Lucia
    Maggiolo, Franco
    Valenti, Daniela
    Blanchi, Sabrina
    Centorrino, Federica
    Comi, Laura
    Di Biagio, Antonio
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2025, 98 (05) : 484 - 490
  • [30] Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting
    Rocabert, Alba
    Borjabad, Beatriz
    Berrocal, Leire
    Blanch, Jordi
    Inciarte, Alexy
    Chivite, Ivan
    Gonzalez-Cordon, Ana
    Torres, Berta
    Ambrosioni, Juan
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    De La Mora, Lorena
    Foncillas, Alberto
    Sempere, Abiu
    Rodriguez, Ana
    Solbes, Estela
    Llobet, Roger
    Miro, Jose M.
    Mallolas, Josep
    Blanco, Jose L.
    De Lazzari, Elisa
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 2961 - 2967
12345